MG
LKFT

Michael Gelband’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Michael Gelband’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-36,372
Closed -$2M – 2357
2021
Q4 		$2M Buy
36,372
+16,294
+81% +$850K 0.02% 759
2021
Q3 		$1.06M Buy
+20,078
New +$1.19M 0.01% 998

Other funds holding LKFT

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's LKFT Position: Q1 2022 in Review

Michael Gelband sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2022, closing a stake of 36,372 shares — an estimated $2M sold.

Michael Gelband first reported a position in LKFT in Q3 2021 and held it in 2 quarters. The position peaked at $2M in Q4 2021. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2022.

  • Michael Gelband reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2022 after selling out during the quarter.
  • Michael Gelband sold 36,372 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2022, an estimated $2M.
  • Michael Gelband first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2021 and held it in 2 quarters.
  • Michael Gelband's Lakefront Biotherapeutics American Depositary Shares position peaked at $2M in Q4 2021.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.